Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) tinted gains of +1.45% (+0.56 points) to US$39.29. The volume of 0.35 Million shares climbed down over an trading activity of 641.09 Million shares. EPS ratio determined by looking at last 12 month figures is -0.02. Over the same time span, the stock marked US$55 as its best level and the lowest price reached was US$26.95. The corporation has a market cap of US$1.63 Billion.
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)’s earnings per share has been growing at a 64.1 percent rate over the past 5 year when average revenue increase was noted as 31.6 percent. The return on equity ratio or ROE stands at -0.2 percent while most common profitability ratio return on investment (ROI) was 2.6 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of -0.1 percent and possesses 74.3 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 1 analysts call it Sell, while 6 think it is Hold. Recently, analysts have updated the overall rating to 2.6. 5 analysts recommended Overweight these shares while 1 recommended Underweight, according to FactSet data.
Check Point Software Technologies Ltd. (NASDAQ:CHKP) is worth US$19.26 Billion and has recently risen 1.44% to US$123.8. The latest exchange of 1.4 Million shares is below its average trading activity of 907.19 Million shares. The day began at US$122.27 but the price moved to US$122.09 at one point during the trading and finally capitulating to a session high of US$123.87. The stock tapped a 52-week high of US$123.69 while the mean 12-month price target for the shares is US$117.85.
Currently, the stock carries a price to earnings ratio of 24.02, a price to book ratio of 5.1, and a price to sales ratio of 10.05. For the past 5 years, the company’s revenue has grown 6.6%, while the company’s earnings per share has grown 9.5%. With an institutional ownership near 76.6%, it carries an earnings per share ratio of 5.16.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 6 brokerage firms polled by Factset Research. At present, 25 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 1 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.62.